Inhibrx/INBX

$34.65

0.12%
-
1D1W1MYTD1YMAX

About Inhibrx

Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2.

Ticker

INBX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Lappe

Employees

166

Headquarters

La jolla, United States

Inhibrx Metrics

BasicAdvanced
$1.65B
Market cap
-
P/E ratio
-$5.03
EPS
2.90
Beta
-
Dividend rate
$1.65B
2.8976
$39.79
$14.31
719.37K
5.245
475.756
475.756
-11%
-80.07%
-475.31%
-93.12%
914.674
37.828
37.846
-17.88%
-39.05%
-48.12%

What the Analysts think about Inhibrx

Analyst Ratings

Majority rating from 3 analysts.
Hold

Price Targets

Average projection from 2 analysts.
2.45% upside
High $36.00
Low $35.00
$34.65
Current price
$35.50
Average price target

Inhibrx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,850% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.6M
1,500%
Net income
$-93.6M
81.04%
Profit margin
-5,850%
-88.68%

Inhibrx Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 66.88%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.12
-$1.08
-$1.10
-$1.73
-
Expected
-$0.84
-$1.03
-$1.01
-$1.04
-$1.04
Surprise
32.7%
4.55%
8.91%
66.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Inhibrx stock?

Inhibrx (INBX) has a market cap of $1.65B as of April 18, 2024.

What is the P/E ratio for Inhibrx stock?

The price to earnings (P/E) ratio for Inhibrx (INBX) stock is 0 as of April 18, 2024.

Does Inhibrx stock pay dividends?

No, Inhibrx (INBX) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Inhibrx dividend payment date?

Inhibrx (INBX) stock does not pay dividends to its shareholders.

What is the beta indicator for Inhibrx?

Inhibrx (INBX) has a beta rating of 2.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Inhibrx stock price target?

The target price for Inhibrx (INBX) stock is $35.5, which is 2.63% above the current price of $34.59. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Inhibrx stock

Buy or sell Inhibrx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing